

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

POSITIVE PROFIT ALERT

This announcement is made by Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2020 and the information currently available to the Board, the Group expects to record an increase in profit attributable to shareholders for the six months ended 30 June 2020 by not less than 40%, as compared with the profit attributable to shareholders of approximately RMB23.7 million for the six months ended 30 June 2019. The expected increase in net profit of the Group was mainly due to the combined effects of (1) increase in the sales of Shuanghuanglian Oral Solutions, the Group’s major products, as a result of increased market demand; (2) contribution from Jiangxi Yongfeng Kangde Pharmaceutical Company Limited* (江西永豐康德醫藥有限公司), a joint venture of the Group and (3) partly offset by the expenses recognised for the extension of exercise period of the share options for the six months ended 30 June 2020.

The Company is still in the process of finalising the consolidated interim results of the Group for the six months ended 30 June 2020. The information contained in this announcement only represents a preliminary assessment based on the unaudited management accounts for the six months ended 30 June 2020 and the information currently available to the Board which has not been reviewed or audited by the auditors of the Company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the six months ended 30 June 2020 which is expected to be published before the end of August 2020.

* For identification purpose only

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 24 August 2020

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming as executive Directors and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.